Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

被引：0

作者：

Chaparro, M. ^{[1
]}

Armuzzi, A. ^{[2
]}

Irving, P. M. ^{[3
,4
]}

Allez, M. ^{[5
]}

Dubinsky, M. C. ^{[6
]}

Sands, B. E. ^{[7
]}

Goetsch, M. ^{[8
]}

Wang, W. ^{[9
]}

Shan, K. ^{[10
]}

Woolcott, J. ^{[11
]}

Bartolome, L. ^{[12
]}

Wosik, K. ^{[13
]}

Panaccione, R. ^{[14
]}

机构：

[1] Univ Autonoma Madrid, Hospital Univ Princesa, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Centro Invest Biomed Red Enfermedades Hepat & Dig, Madrid, Spain

[2] IRCCS Humanitas Res Hosp Rozzano, IBD Ctr, Milan, Italy

[3] Guys & St Thomas NHS Fdn Trust, Gastroenterol, London, England

[4] Kings Coll London, Sch Immunol Microbial Sci, London, England

[5] Univ Paris, Gastroenterol, Hop St Louis, Diderot, France

[6] Icahn Sch Med Mt Sinai, Feinstein IBD Ctr, New York, NY USA

[7] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA

[8] Pfizer AG, Global Clin Dev, Zurich, Switzerland

[9] Pfizer Inc, Biostat, Collegeville, PA USA

[10] Pfizer Inc, Biostat, New York, NY USA

[11] Pfizer Inc, Global Med Affairs Gastroenterol, Collegeville, PA USA

[12] Pfizer Inc, Global Hlth Econ & Outcomes Res Inflammat &, New York, NY USA

[13] Pfizer Inc, Global Med Affairs Gastroenterol, Kirkland, PQ, Canada

[14] Univ Calgary, Inflammatory Bowel Dis Unit, Div Gastroenterol & Hepatol, Calgary, AB, Canada

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP42

引用

页码：I107 / I110

页数：5

共 50 条

[31] Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme
Regueiro, Miguel
Siegmund, Britta
Yarur, Andres J.
Steinwurz, Flavio
Gecse, Krisztina B.
Goetsch, Martina
Bhattacharjee, Abhishek
Wu, Joseph
Green, Jesse
McDonnell, Aoibhinn
Crosby, Catherine
Lazin, Krisztina
Branquinho, Diogo
Modesto, Irene
Abreu, Maria T.
JOURNAL OF CROHNS & COLITIS, 2024, 18 (10): : 1596 - 1605
[32] MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
Sands, Bruce E.
Vermeire, Severine
Dubinsky, Marla C.
Feagan, Brian G.
Panaccione, Remo
Jairath, Vipul
Yarur, Andres J.
Chiorean, Michael V.
Panes, Julian
Goetsch, Martina
Rabbat, Christopher J.
Shah, Pooja
Wu, Joseph
Ghosh, Subrata
GASTROENTEROLOGY, 2023, 164 (06) : S1084 - S1085
[33] Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12 (sep, 10.1093/ibd/izae229/7778239, 2024)
Armuzzi, Alessandro
Rubin, David T.
Schreiber, Stefan
Panes, Julian
Fellmann, Marc
Bartolome, Lauren
Gruben, David
Goetsch, Martina
Bhattacharjee, Abhishek
Chaparro, Maria
Dubinsky, Marla C.
INFLAMMATORY BOWEL DISEASES, 2024,
[34] Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
Magro, Fernando
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Danese, Silvio
Jairath, Vipul
Goetsch, Martina
Bhattacharjee, Abhishek
Wu, Joseph
Branquinho, Diogo
Modesto, Irene
Feagan, Brian G.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S772 - S773
[35] Efficacy and Safety of Etrasimod in Patients With Ulcerative Colitis Stratified by Body Mass Index: A Post Hoc Analysis From the ELEVATE UC Clinical Program
Yarur, Andres J.
Long, Millie D.
Torres, Joana
Nandi, Neilanjan
Cross, Raymond K.
Abbatemarco, Arcangelo M.
Blanco, David
Niezychowski, Wojciech
Crosby, Catherine M.
Wu, Joseph
Pradeep, Gokul
Goetsch, Martina
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1026 - S1027
[36] EFFICACY OF ETRASIMOD AT WEEK 52 AMONG SUBJECTS WHO REACHED CLINICAL RESPONSE AT WEEK 12: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
Vermeire, Severine
Sands, Bruce E.
Dubinsky, Marla C.
Feagan, Brian G.
Panaccione, Remo
Jairath, Vipul
Yarur, Andres J.
Chiorean, Michael V.
Panes, Julian
Goetsch, Martina
Rabbat, Christopher J.
Shah, Pooja
Wu, Joseph
Ghosh, Subrata
GASTROENTEROLOGY, 2023, 164 (06) : S1085 - S1085
[37] Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Lichtenstein, Gary R.
Allegretti, Jessica R.
Loftus Jr, Edward, V
Irving, Peter M.
Banerjee, Rupa
Charabaty, Aline
Kuehbacher, Tanja
Bananis, Eustratios
Woolcott, John C.
Dalam, Alexis B.
Lazin, Krisztina
Keating, Michael
Mcdonnell, Aoibhinn
Danese, Silvio
INFLAMMATORY BOWEL DISEASES, 2025,
[38] Etrasimod efficacy in patients with mildly to moderately active Ulcerative Colitis (modified Mayo score 4-6) in the phase 3 ELEVATE UC clinical programme
Yarur, A. J.
D'Haens, G. R.
Baert, F.
Goetsch, M.
Zang, C.
Gu, G.
Mazur, R.
Keating, M.
Kudlacz, E.
Sidhu, S.
Wosik, K.
Danese, S.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1460 - i1462
[39] Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial
Vermeire, S.
Sands, B. E.
Dubinsky, M. C.
Feagan, B. G.
Panaccione, R.
Jairath, V.
Yarur, A.
Chiorean, M.
Panes, J.
Goetsch, M.
Rabbat, C. J.
Shah, P.
Wu, J.
Ghosh, S.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 709 - 710
[40] ACHIEVEMENT OF CORTICOSTEROID-FREE CLINICAL ENDPOINTS IN SUBJECTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
Sands, Bruce E.
Rubin, David T.
Panes, Julian
Gecse, Krisztina
Leung, Yvette
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
GASTROENTEROLOGY, 2023, 164 (06) : S1084 - S1084

← 1 2 3 4 5 →